Regenxbio (NASDAQ:RGNX) has received varied opinions from 4 analysts over the past quarter, all of which are bullish. The average 12-month price target is $38.25, reflecting a 2.46% increase from the previous target. Key analysts from HC Wainwright & Co. and Goldman Sachs have maintained or raised their buy ratings. Regenxbio, a biotechnology company, has shown solid revenue growth but faces challenges with lower growth rates compared to peers. The company maintains strong financial metrics with a balanced debt approach.